ProCE Banner Activity

Biomarkers of Response or Resistance to Ribociclib + Endocrine Therapy for Advanced Breast Cancer: Pooled Analysis of MONALEESA Phase III Trials

Slideset Download
Conference Coverage
In this pooled analysis of ctDNA from 3 MONALEESA breast cancer studies, multiple potential biomarkers of ribociclib sensitivity and resistance were identified.

Released: May 31, 2020

Expiration: May 30, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Jazz Pharmaceuticals

Karyopharm Therapeutics

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer and EMD Serono